Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early High-dose Erythropoietin After OHCA
NCT00719498Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2003
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, open-label trial of epoetin alfa in cardiac arrest (SCA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Mortality at 28 days and Neurological Outcome at 28 days. Started Nov 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT00719498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719498.